Zobrazeno 1 - 10
of 28
pro vyhledávání: '"D. Rekalov"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Osteoarthritis and Cartilage. 31:S411
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01219a49f1dd367c712bfb53c812a93f
https://doi.org/10.1016/j.joca.2023.01.478
https://doi.org/10.1016/j.joca.2023.01.478
Autor:
Michael E. Weinblatt, Asta Baranauskaite, Jaroslaw Niebrzydowski, Eva Dokoupilova, Agnieszka Zielinska, Janusz Jaworski, Artur Racewicz, Margarita Pileckyte, Krystyna Jedrychowicz‐Rosiak, Soo Yeon Cheong, Jeehoon Ghil, S. Sokolovic, M. Mekic, N. Prodanovic, B. Gajic, E. Karaselimovic‐Dzambasovic, B. Pojskic, A. Toncheva, P. Dimitar, L. Rodina, M. Geneva‐Popova, I. Staykov, R. Stoilov, L. Podrazilova, Z. Mosterova, G. Simkova, J. Kopackova, Z. Stejfova, J. Vencovsky, Z. Urbanova, L. Janska, D. Galatíkova, S. Stropuviene, I. Sniuoliene, K. Sitek‐Ziolkowska, M. Rell‐Bakalarska, R. Kolasa, S. Daniluk, B. Sliwowska, M. Bartosik‐Twardowska, J. Brzezicki, M. Konieczny, S. Jeka, J. Choe, S. Bae, Y. Kang, L. Prystupa, Z. Vyacheslav, I. Gasanov, R. Yatsyshyn, D. Rekalov, O. Iaremenko, M. Stanislavchuk, V. Tseluyko
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
Objective SB5 is a biosimilar agent for adalimumab (ADA). The aim of this study was to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of SB5 in comparison with reference ADA in patients with rheumatoid arthritis (RA). Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd57157bedc7b756d3a592490108b340
https://doi.org/10.1002/art.40336
https://doi.org/10.1002/art.40336
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
D. Rekalov, D. Nikitina
Publikováno v:
Rheumatoid arthritis – prognosis, predictors and outcome.
Background Recent achievements have established that the very first years since the development of the RA are decisive in terms of the progression of the pathological process and the prediction of its remote consequences. This substantiated the need
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed9673cc91de61ee1cf1799c64847cc1
https://doi.org/10.1136/annrheumdis-2018-eular.2398
https://doi.org/10.1136/annrheumdis-2018-eular.2398
Publikováno v:
Saturday, 16 JUNE 2018.
Background RA is characterized by not only joints destruction, but also of other organs and systems, particularly, lungs, heart, blood vessels, kidneys, etc. Nephropathy is currently the leading symptomatic complex of Rheumatoid Arthritis (RA), with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86d11a871db285a2b3d8d6266ddec058
https://doi.org/10.1136/annrheumdis-2018-eular.1713
https://doi.org/10.1136/annrheumdis-2018-eular.1713
Publikováno v:
Osteoarthritis.
Background Gout is the most common cause of an inflammatory arthritis in men elder than 30 years, varies up to 1,7% of the total morbidity. One of the most common complication of chronic gout is gouty nephropathy with the morphological signs of kidne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::368a2a27b426bea59f96a6744195f54e
https://doi.org/10.1136/annrheumdis-2018-eular.3020
https://doi.org/10.1136/annrheumdis-2018-eular.3020
Autor:
D. Rekalov, N. Rozdolska
Publikováno v:
Cytokines and inflammatory mediators.
Background Systemic disorganisation of connective tissue with early metabolic disorder of its matrix is an inherent characteristic feature of rheumatoid arthritis (RA). The determination of the key extracellular matrix molecules in patients with earl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06d3dc2d784d501c942853c546cb50b3
https://doi.org/10.1136/annrheumdis-2018-eular.1970
https://doi.org/10.1136/annrheumdis-2018-eular.1970
Publikováno v:
Georgian medical news. (274)
Objective of the study layed in assessment of the pathophysiological relation between cell-mediated immunity (tumor necrosis factor-alpha (TNF-α) inflammatory cytokine) activation and renal dysfunction in the patients with early rheumatoid arthritis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::40d2e1b92567255e03f491251cd111e9
https://pubmed.ncbi.nlm.nih.gov/29461232
https://pubmed.ncbi.nlm.nih.gov/29461232
Autor:
D. Rekalov, D.-H. Yoo, Won Park, P. Géher, D. Andersone, Janusz Jaworski, Sang Joon Lee, Marek Brzosko, Boycho A Oparanov, C. Pacheco-Tena, R. Kausiene
Publikováno v:
Annals of the Rheumatic Diseases. 73:235.1-235
Background CT-P13 is a biosimilar to innovator infliximab (INX) approved by the European Medicines Agency. From the PLANETRA, which is randomized, double-blind, active-controlled trial to assess efficacy and safety of CT-P13 in rheumatoid arthritis (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::566b02f8e2b170fd85300f2c9703af3b
https://doi.org/10.1136/annrheumdis-2014-eular.3707
https://doi.org/10.1136/annrheumdis-2014-eular.3707